[{"data":1,"prerenderedAt":186},["ShallowReactive",2],{"drug-interferon-beta-1a":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":23,"regimens":38,"contraindications":64,"warnings":74,"renal":82,"monitoring":83,"interactions":84,"review":85,"examples":88,"atc":94,"iran":96,"usApproval":124,"links":130,"populations":151},"interferon-beta-1a",1,{"fa":7,"en":8},"اینترفرون بتا-۱a (عضلانی)","Interferon beta-1a (IM)","antineoplastic-immunomodulating",{"fa":11,"en":12},"اینترفرون","Interferon",[14],{"name":15,"market":16},"Avonex","US",[18,19,20,21,22],"avonex","آوونکس","cinnovex","سینووکس","interferon beta",[24],{"id":25,"form":26,"route":27,"label":28,"concentration":29,"markets":33,"refs":34},"pfs-30","injection","im","30 mcg\u002F0.5 mL prefilled syringe or autoinjector",{"amount":30,"unit":31,"perVolumeMl":32},30,"mcg",0.5,[16],[35],{"source":36,"section":37},"fda-avonex","3",[39],{"id":40,"disease":41,"label":42,"population":45,"type":49,"unit":31,"dose":50,"refs":51,"durationDays":54,"notes":55},"ms","multiple-sclerosis",{"fa":43,"en":44},"ام‌اس عودکننده بزرگسال — ۳۰ mcg عضلانی یک بار در هفته","Relapsing MS, adults — 30 mcg IM once a week",{"minAge":46},{"value":47,"unit":48},18,"year","fixed",{"perDose":30,"dosesPerDay":5},[52],{"source":36,"section":53},"2.1",{"min":5,"max":5},[56],{"text":57,"refs":60},{"fa":58,"en":59},"برای کاهش علائم شبه‌آنفلوانزا: شروع ۷٫۵ mcg و هر هفته ۷٫۵ mcg افزایش طی ۳ هفته. مسکن\u002Fتب‌بر روز تزریق.","To reduce flu-like symptoms: start 7.5 mcg and increase by 7.5 mcg weekly over 3 weeks. Analgesic\u002Fantipyretic on injection days.",[61,62],{"source":36,"section":53},{"source":36,"section":63},"2.3",[65],{"id":66,"severity":67,"text":68,"refs":71},"hyper","block",{"fa":69,"en":70},"حساسیت به اینترفرون بتای طبیعی یا نوترکیب.","Hypersensitivity to natural or recombinant interferon beta.",[72],{"source":36,"section":73},"4",[75],{"text":76,"refs":79},{"fa":77,"en":78},"افسردگی، خودکشی و سایکوز؛ آسیب کبد؛ آنافیلاکسی؛ نکروز محل تزریق؛ نارسایی قلب؛ کاهش شمارش خون؛ میکروآنژیوپاتی ترومبوتیک؛ تشنج.","Depression, suicide and psychosis; hepatic injury; anaphylaxis; injection-site necrosis; heart failure; decreased blood counts; thrombotic microangiopathy; seizures.",[80],{"source":36,"section":81},"5",[],[],[],{"status":86,"reviewer":87,"date":87},"unverified",null,[89],{"regimen":40,"formulation":25,"input":90,"expect":93},{"ageYears":91,"weightKg":92},35,65,{"perDose":30,"mlPerDose":32},[95],"L03AB07",{"status":97,"forms":98,"refs":119},"registered",[99,103,107,111,115],{"code":100,"en":101,"fa":102},"22378","INTERFERON B 1A 30 MCG PREFILLED SYRINGE","سرنگ از پیش پرشده اینترفرون B ۱ A ۳۰ میکروگرم",{"code":104,"en":105,"fa":106},"02667","INTERFERON B 1A 30 MCG VIAL","ویال اینترفرون B ۱ A ۳۰ میکروگرم",{"code":108,"en":109,"fa":110},"02666","INTERFERON BETA-1A INJECTION PARENTERAL 12000000 [iU] 0.5MILLILITER","فرآورده تزریقی اینترفرون بتا–۱ A ۱۲۰۰۰۰۰۰ واحد بین‌المللی ۰٫۵ میلی‌لیتر",{"code":112,"en":113,"fa":114},"51988","INTERFERON BETA-1A INJECTION PARENTERAL 12000000 [iU]\u002F1mL 0.5MILLILITER","فرآورده تزریقی اینترفرون بتا–۱ A ۱۲۰۰۰۰۰۰ واحد بین‌المللی \u002F ۱ میلی‌لیتر ۰٫۵ میلی‌لیتر",{"code":116,"en":117,"fa":118},"52034","INTERFERON BETA-1A INJECTION PARENTERAL 12000000 [iU] 1.5MILLILITER","فرآورده تزریقی اینترفرون بتا–۱ A ۱۲۰۰۰۰۰۰ واحد بین‌المللی ۱٫۵ میلی‌لیتر",[120],{"source":121,"section":122,"url":123},"darooyab-generic","G-4579\u002FInterferon-Beta-1A","https:\u002F\u002Fwww.darooyab.ir\u002FG-4579\u002FInterferon-Beta-1A",{"kind":125,"refs":126,"id":129},"BLA",[127],{"source":36,"section":128},"SPL approval \u002F marketing category","BLA103628",[131,134,138,142,145,148],{"kind":132,"url":133,"label":129},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=103628",{"kind":135,"url":136,"label":137},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=d70a39cc-de15-4c12-a1ec-8063b69ea0e1","FDA Avonex",{"kind":139,"url":140,"label":141},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa693040.html","Interferon Beta-1a Intramuscular Injection",{"kind":139,"url":143,"label":144},"https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa604005.html","Interferon Beta-1a Subcutaneous Injection",{"kind":146,"url":147,"label":95},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=L03AB07",{"kind":149,"url":123,"label":150},"darooyab","Interferon-Beta-1A",{"pregnancy":152,"lactation":161,"pediatric":169,"geriatric":178},{"level":153,"text":154,"quote":157,"refs":158},"caution",{"fa":155,"en":156},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Data from a large population-based cohort study, as well as other published studies over several decades, have not identified a drug-associated risk of major birth defects with the use of interferon beta products during early pregnancy.",[159],{"source":36,"section":160},"8.1",{"level":153,"text":162,"quote":165,"refs":166},{"fa":163,"en":164},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary Limited published literature has described the presence of interferon beta-1a products in human milk at low levels.",[167],{"source":36,"section":168},"8.2",{"level":170,"text":171,"quote":174,"refs":175},"not-established",{"fa":172,"en":173},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in pediatric patients have not been established.",[176],{"source":36,"section":177},"8.4",{"level":153,"text":179,"quote":182,"refs":183},{"fa":180,"en":181},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Clinical studies of AVONEX did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients.",[184],{"source":36,"section":185},"8.5",1792191549820]